Abstract
Elderly patients (≥70 years) currently make up about one half of all lung cancer patients in the USA. The normal aging process combined most often with years of smoking leads to physiologic limitations which make aggressive multimodality therapy more challenging. Large modern studies which employed aggressive chemotherapy plus radiotherapy (RT) found that fit elderly patients experienced more myelosuppression and specific non-hematologic toxicities than younger individuals. Despite some degree of increased toxicity from combined modality therapy, it appeared that the fit elderly patients had similar disease control and survival rates as younger patients. Additionally, studies have shown that elderly patients had better survival with the more aggressive regimens of concurrent chemotherapy and radiotherapy rather than sequential therapy or RT alone. These findings suggest that fit elderly patients with locally advanced NSCLC should be encouraged to receive combined modality therapy. Recent clinical trials have been performed specifically for elderly patients. These studies should help clinicians optimize future treatment for the elderly. Research should focus on decreasing treatment toxicity in all patients but especially in the elderly. Treatment-related toxicity may be lessened with the use of newer radiation delivery techniques and novel targeted therapy. Additionally, more studies are needed for elderly patients and those with limited performance status who are grossly underrepresented in current clinical trials.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Perez CA. Non-small cell carcinoma of the lung: dose-time parameters. Cancer Treat Symp. 1985;2:131–42.
Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst. 1996;88:1210–5.
Komaki R, Seiferheld W, Curran W, et al. Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): analysis of failures in a phase III study (RTOG 9410)(abstract). Int J Radiat Oncol Biol Phys. 2000;48:113.
Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma. Lung Cancer. 1994;10 Suppl 1:S239–244.
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311:899–909.
Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88–08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. 1995;87:198–205.
Furse KFM, Kawahara M, Nishikawa H, Takada Y, Kudoh S, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol. 1999;17:2692–9.
Komaki RSW, Curran W, et al. Sequential vs. concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): analysis of failures in a phase III study (RTOG 9410) (abstract). Int J Radiat Oncol Biol Phys. 2004;48:113.
Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10–30.
Langer CJ, Hsu J, Curran WJ, et al. Elderly patients with locally advanced non-small cell lung cancer (LA NSCLC) benefit from combined modality therapy, secondary analysis of radiation therapy oncology group (RTOG) 94–10. Proc ASCO. 2002;21:299a.
Langer CJ, Scott C, Byhardt RW. Effect of advanced age on outcome in radiation therapy oncology group studies of locally advanced NSCLC (LA-NSCLC). Lung Cancer. 2000;29:104.
Rocha Lima CM, Herndon 2nd JE, Kosty M, et al. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer. 2002;94:181–7.
Schild SE, Stella PJ, Geyer SM, et al. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol. 2003;21:3201–6.
Schild SE, Stella PJ, Geyer SM, et al. Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;54:370–8.
Schild SE, Mandrekar SJ, Jatoi A, et al. The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer. Cancer. 2007;110:363–8.
Atagi S, Kawahara M, Ogawara M, et al. Phase II trial of daily low-dose carboplatin and thoracic radiotherapy in elderly patients with locally advanced non-small cell lung cancer. Jpn J Clin Oncol. 2000;30:59–64.
Atagi S, Kawahara M, Yokoyama A, et al. Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol. 2012;13:671–8.
Videtic G, Vokes E, Turrisi A, et al. The survival of patients treated for stage III non-small cell lung cancer in North America has increased during the past 25 years. (Abstract 2557). The 39th annual meeting of the American Society of Clinical Oncology. 2003; Chicago: ASCO. p. 291.
Langer CJ, Hsu C, Curran WJ, et al. Elderly patients (pts) with locally advanced non-small cell lung cancer (LA-NSCLC) benefit from combined modality therapy: secondary analysis of Radiation Therapy Oncology Group (RTOG) 94–10. In: Proceedings of the American Society of Clinical Oncology. Vol 21. Lippincott Williams & Wilkins; Philadelphia, PA, 2002. p. 299a.
Jeremic B, Shibamoto Y, Milicic B, et al. A phase II study of concurrent accelerated hyperfractionated radiotherapy and carboplatin/oral etoposide for elderly patients with stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 1999;44:343–8.
Coate LE, Massey C, Hope A, et al. Treatment of the elderly when cure is the goal: the influence of age on treatment selection and efficacy for stage III non-small cell lung cancer. J Thorac Oncol. 2011;6:537–44.
Jatoi A, Schild SE, Foster N, et al. A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422). Ann Oncol. 2010;21:2040–4.
Jensen AD, Munter MW, Bischoff HG, et al. Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab: the NEAR trial. Cancer. 2011;117:2986–94.
Sejpal S, Komaki R, Tsao A, et al. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer. 2011;117:3004–13.
Semrau S, Klautke G, Virchow JC, et al. Impact of comorbidity and age on the outcome of patients with inoperable NSCLC treated with concurrent chemoradiotherapy. Respir Med. 2008;102:210–8.
Semrau S, Klautke G, Fietkau R. Baseline cardiopulmonary function as an independent prognostic factor for survival of inoperable non-small-cell lung cancer after concurrent chemoradiotherapy: a single-center analysis of 161 cases. Int J Radiat Oncol Biol Phys. 2011;79:96–104.
Langer CJ, Hsu C, Curran WJ, et al. Elderly patients with locally advanced non-small cell lung cancer (LA NSCLC) benefit from combined modality therapy, secondary analysis of radiation therapy oncology group (RTOG) 94–10. Proc Am Soc Clin Oncol. 2002;21:299a (abstract 1193).
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag London
About this chapter
Cite this chapter
Schild, S.E. (2013). Locally Advanced Non-Small Cell Lung Cancer in the Elderly: What Combination of Therapy Is Best?. In: Gridelli, C., Audisio, R. (eds) Management of Lung Cancer in Older People. Springer, London. https://doi.org/10.1007/978-0-85729-793-8_13
Download citation
DOI: https://doi.org/10.1007/978-0-85729-793-8_13
Published:
Publisher Name: Springer, London
Print ISBN: 978-0-85729-792-1
Online ISBN: 978-0-85729-793-8
eBook Packages: MedicineMedicine (R0)